SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma
This study is testing a targeted cancer medicine called mirdametinib for children and young adults with slow-growing brain or spinal cord tumors known as low-grade gliomas. Researchers want to see how safe this treatment is and how well it works against these types of tumors.
This trial is open to patients between 2 and 25 years old who have a confirmed or suspected slow-growing brain or spinal tumor. Participants must also meet specific health guidelines, such as having healthy eyes, liver, and lungs.
Participants will take the study drug, mirdametinib, which is a pill designed to block specific signals that help tumor cells grow. Regular health checks and tests will be done to monitor safety and see how the body and tumor respond to the treatment.
The study is currently active and recruiting patients. It is taking place in Memphis, Tennessee, in the United States.
- 1Testing a targeted oral medicine called mirdametinib for young patients with slow-growing brain tumors.
- 2Open to children, adolescents, and young adults ages 2 to 25.
- 3Currently recruiting participants at a location in Memphis, Tennessee.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.